<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-C
Report by Issuer of Securities Quoted on Nasdaq
Interdealer Quotation System
Filed pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934 and Rule 13a-17
or 15d-17 thereunder
BOSTON LIFE SCIENCES, INC.
- --------------------------------------------------------------------------------
(Exact name of issuer as specified in charter)
33 Newbury Street, Suite 300, Boston, Massachusetts 02116
-------------------------------------------------------------------
(Address of principal executive offices)
Issuer's telephone number, including area code: (617) 425-0200
------------------
I. CHANGE IN NUMBER OF SHARES OUTSTANDING
Indicate any change (increase or decrease) of 5% or more in the number of shares
outstanding:
1. Title of Security Common Stock
----------------------------------------------------------
2. Number of shares outstanding before the change 99,959,153
-----------------------------
3. Number of shares outstanding after the change 104,959,153
------------------------------
4. Effective date of change June 28, 1996
---------------------------------------------------
5. Method of Change:
Specify method (such as merger, acquisition, exchange, distribution, stock
split, reverse split, acquisition of stock for treasury, etc.)
Issuance in Private placement
---------------------------------------------------------------------------
Give brief description of transaction Private placement of 5 million
---------------------------------
shares of Common Stock
---------------------------------
II. CHANGE IN NAME OF ISSUER
1. Name prior to change
-------------------------------------------------------
2. Name after change
----------------------------------------------------------
3. Effective date of charter amendment changing name
--------------------------
4. Date of shareholder approval of change, if required
------------------------
Date July 8, 1996 /s/ S. David Hillson
----------------- -------------------------------------
S. David Hillson, President and
Chief Executive Officer
